Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per specialist: Arnon Nagler, MD
Woman and Man Max 99 years
Arnon Nagler, MD
Update Il y a 5 ans
Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia
The aim of the study is to test the safety and efficacy of BL-8040 (a CXCR4 antagonist) in improving the response to imatinib in CML patients not achieving an optimal response with imatini...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Arnon Nagler, MD
Update Il y a 5 ans
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients
BKT-140 drug substance is a highly selective chemokine receptor (CXCR4) antagonist, which is developed by Biokine as a novel therapy for Multiple Myeloma (MM, a type of blood cancer). The ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Arnon Nagler, MD
Update Il y a 5 ans
Treosulfan-based Conditioning for Transplantation in AML/MDS
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan, will reduce toxicity after allogeneic transplantation while improving myeloablation...
Country
Israel
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Arnon Nagler, MD
Update Il y a 5 ans
Nilotinib Pre and Post Allogeneic Stem Cell Transplantation
Current therapeutic results in advanced chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) are rather disappointing. Most of these patients will eventually undergo a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Arnon Nagler, MD
Update Il y a 5 ans
TevaGastrim for Stem Cell Mobilization Sibling Donors
The aim of this study is to evaluate the efficacy of TevaGastrim which is a biosimilar version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number of stem cells f...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Arnon Nagler, MD
Update Il y a 5 ans
Mozobil for Autologous Stem Cell Mobilization
The aim of this study is to evaluate Plerixafor (MOZOBIL) plus recombinant human G-CSF (G-CSF) efficiency in mobilizing sufficient number of stem cells from Lymphoma (NHL and HL) patients ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Arnon Nagler, MD
Update Il y a 5 ans
Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma
High-dose chemotherapy and autologous stem-cell transplantation have an established role in the treatment of aggressive Non-Hodgkin's lymphoma (NHL) when refractory to first line chemother...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Arnon Nagler, MD
Update Il y a 5 ans
Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Arnon Nagler, MD
Update Il y a 5 ans
Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB)
The aim of this study is to evaluate the safety profile and tolerability of infusion of cord blood cells expanded in the lab and to evaluated whether through the infusion of expanded cells...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Arnon Nagler, MD
Update Il y a 5 ans
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
The study hypotheses is that the introduction of dose escalated thiotepa, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving di...
Country
None
organs
None
Specialty
None
Opened trial
More information
1
2
Next